BLTE — BELITE BIO, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1889109 ·
Last close
$158.87
Market Cap
$6.40B
52W High
$181.56
52W Low
$130.00
ADV30
167,401
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -32,684,000 | -26,938,000 | 811,271,000 | — | 15,483,000 |
| Dec 2025 | 0 | — | -28,077,000 | -25,324,000 | 780,556,000 | 352,932,000 | 10,070,000 |
| Sep 2025 | 0 | — | -23,018,000 | -21,690,000 | 282,393,000 | 157,034,000 | 8,311,000 |
| Jun 2025 | 0 | — | -17,596,000 | -16,320,000 | 156,407,000 | — | 6,522,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-14,986,000
Investing CF
$-329,748,000
Financing CF
$549,893,000
CapEx
$-6,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.53
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-185,258,000
Inventory
—
Receivables
$718,000
ST Investments
$139,490,000
EBIT TTM
$-94,776,000
Pretax Income TTM
$-90,272,000
Interest Exp TTM
—
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -84,208,000 | -77,611,000 | 780,556,000 | 10,070,000 | — | -36,988,000 |
| Dec 2024 | 0 | -39,996,000 | -36,144,000 | 152,132,000 | 6,311,000 | — | -29,234,000 |
| Dec 2023 | 0 | -31,668,000 | -31,632,000 | 94,642,000 | 4,211,000 | — | -29,837,000 |
| Dec 2022 | 0 | -12,821,000 | -12,648,000 | 44,273,000 | 2,772,000 | — | -11,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.14
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LQDA | Liquidia Corp | $6.29B | $70.27 | — |
| COGT | Cogent Biosciences, Inc. | $6.29B | $36.23 | — |
| AMRX | Amneal Pharmaceuticals, Inc. | $6.19B | $17.78 | — |
| ERAS | Erasca, Inc. | $6.16B | $17.60 | — |
| TVTX | Travere Therapeutics, Inc. | $6.06B | $65.22 | — |
News headlines (Yahoo Finance, 1h cache)
Belite Bio to Host Virtual Commercial Day on September 2, 2026
2026-08-24 20:00 · Yahoo
Belite Bio (BLTE) Could Be 21% Undervalued On FDA Priority Review News
2026-08-14 20:10 · Yahoo
Belite Bio (BLTE) Stock Looks Fully Valued After A 431% Run
2026-08-14 15:11 · Yahoo
Belite Bio Inc (BLTE) (Q2 2026) Earnings Call Highlights: FDA Priority Review and Strong Cash ...
2026-08-14 07:00 · Yahoo
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
2026-08-11 20:01 · Yahoo
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
2026-08-06 12:00 · Yahoo
Belite Bio to Participate in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
2026-07-15 12:00 · Yahoo
Belite Bio Eyes Priority FDA Review as Tinlarebant Targets Stargardt Disease
2026-07-10 03:02 · Yahoo
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
2026-07-06 12:00 · Yahoo
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
2026-06-12 18:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.